On Mar. 9, 2020,  researchers from the National Institute of Allergy and Infectious Diseases (NIAID), part of the NIH, reported finding a new approach to direct the body to make a specific antibody against HIV led to sustained production of that antibody for more than a year among participants in a NIH clinical trial.

This drug-delivery technology uses a harmless virus to deliver an antibody gene into human cells, enabling the body to generate the antibody over an extended time. Researchers from NIAID reported the findings on Mar. 9 in an oral presentation at the 2020 Conference on Retroviruses and Opportunistic Infections.